Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 GFR decline as an end point in trials of CKD: a viewpoint from the FDA.

Literature DB >> 25446026

GFR decline as an end point in trials of CKD: a viewpoint from the FDA.

Aliza Thompson¹, John Lawrence², Norman Stockbridge².

Abstract

Mesh：

Year: 2014 PMID： 25446026 DOI： 10.1053/j.ajkd.2014.09.006

Source DB: PubMed Journal: Am J Kidney Dis ISSN： 0272-6386 Impact factor: 8.860

Keyword Cloud
Cited

× No keyword cloud information.

20 in total

1. End Points for Clinical Trials in Primary Hyperoxaluria.

Authors: Dawn S Milliner; Tracy L McGregor; Aliza Thompson; Bastian Dehmel; John Knight; Ralf Rosskamp; Melanie Blank; Sixun Yang; Sonia Fargue; Gill Rumsby; Jaap Groothoff; Meaghan Allain; Melissa West; Kim Hollander; W Todd Lowther; John C Lieske
Journal: Clin J Am Soc Nephrol Date: 2020-03-12 Impact factor: 8.237

Review 2. FDA Regulatory Perspectives for Studies on Hemodialysis Vascular Access.

Authors: Frank P Hurst; Robert E Lee; Aliza M Thompson; Brian D Pullin; Douglas M Silverstein
Journal: Clin J Am Soc Nephrol Date: 2017-07-24 Impact factor: 8.237

3. Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices.

Authors: Eiichiro Kanda; Naoki Kashihara; Kunihiro Matsushita; Tomoko Usui; Hirokazu Okada; Kunitoshi Iseki; Kenichi Mikami; Tetsuhiro Tanaka; Takashi Wada; Hirotaka Watada; Kohjiro Ueki; Masaomi Nangaku
Journal: Clin Exp Nephrol Date: 2018-12 Impact factor: 2.801

4. Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data.

Authors: Morgan E Grams; Yingying Sang; Shoshana H Ballew; Kunihiro Matsushita; Brad C Astor; Juan Jesus Carrero; Alex R Chang; Lesley A Inker; Timothy Kenealy; Csaba P Kovesdy; Brian J Lee; Adeera Levin; David Naimark; Michelle J Pena; Jesse D Schold; Varda Shalev; Jack F M Wetzels; Mark Woodward; Ron T Gansevoort; Andrew S Levey; Josef Coresh
Journal: J Am Soc Nephrol Date: 2019-07-10 Impact factor: 10.121

Review 5. Developing Treatments for Chronic Kidney Disease in the 21st Century.

Authors: Matthew D Breyer; Katalin Susztak
Journal: Semin Nephrol Date: 2016-11 Impact factor: 5.299

Review 6. The kidney transcriptome, from single cells to whole organs and back.

Authors: Shizheng Huang; Xin Sheng; Katalin Susztak
Journal: Curr Opin Nephrol Hypertens Date: 2019-05 Impact factor: 2.894

7. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.

Authors: Alan S L Yu; Chengli Shen; Douglas P Landsittel; Peter C Harris; Vicente E Torres; Michal Mrug; Kyongtae T Bae; Jared J Grantham; Frederic F Rahbari-Oskoui; Michael F Flessner; William M Bennett; Arlene B Chapman
Journal: Kidney Int Date: 2017-12-28 Impact factor: 10.612